Ryvu Therapeutics SA (9Y4) Income Statement
Ryvu Therapeutics SA Income Statement
Last quarter (Q2 2026), Ryvu Therapeutics SA's total revenue was $11.99M, a decrease of 3.35% from the same quarter last year. In Q2, Ryvu Therapeutics SA's net income was $-13.06M. See Ryvu Therapeutics SA’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 62.25M | $ 77.97M | $ 46.86M | $ 38.80M | $ 11.19M | |
| $ -117.03M | $ 58.39M | $ 29.31M | $ 21.40M | $ -2.54M | |
| $ 5.12M | $ 180.49M | $ 130.25M | $ 93.07M | $ 75.98M | |
| Depreciation and Amortization | $ 9.44M | $ 10.49M | $ 10.97M | $ 12.90M | $ 12.56M |
| $ -112.71M | $ -96.83M | $ -81.04M | $ -65.21M | $ -65.96M | |
| $ -122.15M | $ -122.10M | $ -100.95M | $ -78.42M | $ -103.78M | |
| $ 21.01M | $ 10.96M | $ 8.84M | $ -773.00K | $ -363.00K | |
| $ -101.14M | $ -111.14M | $ -92.11M | $ -79.19M | $ -78.96M | |
| $ -101.23M | $ -111.44M | $ -92.11M | $ -83.78M | $ -79.08M | |
| Per Share Metrics | |||||
| Basic EPS | $ -4.38 | $ -4.82 | $ -4.02 | $ -4.57 | $ -4.31 |
| Diluted EPS | $ -4.38 | $ -4.82 | $ -4.02 | $ -4.57 | $ -4.31 |
| Weighted Average Shares Outstanding | 23.12M | 23.12M | 22.90M | 18.33M | 18.36M |
| Weighted Average Shares Outstanding (Diluted) | 23.12M | 23.12M | 22.90M | 18.33M | 18.36M |
Currency in PLN